PI     PL     

 

Kisqali 200mg Film Coated Tablets

Kisqali is indicated in combination with:

· a non-steroidal aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, as initial endocrine-based therapy; or

· fulvestrant for the treatment of men and postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.

 

References:

1. Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381:307-316

KIS BC 23 19 August 19
×

Medical Information Request

×

Ask Speakers